

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/902,176
				Filing Date	July 10, 2001
				First Named Inventor	Schreiber
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	25481-P001US
Sheet	1	of	2		

RECEIVED  
JAN 29 2002  
NYSER 1600/2900

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
4/1		WO 00/31293	06-02-2000	Morris	Whole document

Examiner Signature	<i>John E. ...</i>	Date Considered	6/16/05
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/902.176		
		Filing Date	July 10, 2001		
		First Named Inventor	Schreiber		
		Group Art Unit	1645		
		Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	25481-P001US

RECEIVED  
JAN 29 2002  
TECH CENTER 1600/2900


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
LS	-	SMITH et al.; Human Tumor Necrosis Factor Receptor mRNA; Database EMHUM6 'Online!'; ID HSNFR, June 1990	
	-	SYNERGEN, Inc.; 40kD TNF Inhibitor Precursor; Database GCG_GENESEQ_P 'Online!'; R11001 January 1991	
	-	SMITH; Fibroblast Derived TNF-R; Database GCG_GENESEQ_P 'Online!'; ID: R42058, April 1994	
	-	BELTINGER, et al.; Physical Mapping and Genomic Structure of the Human TNFR2 Gene; Genomics 35, 94-11 (1996); Article No. 0327; 1996	
	-	RAU, et al.; Polymorphisms of Tumor Necrosis Factor Receptor 2 are Not Associated with Insulin-Dependent diabetes Mellitus or Graves' Disease; Tissue Antigens; Vol 49, No. 5, 1997, pages 535-536	
	-	VAN DEVENTER; Immunomodulation of Chron's Disease Using TNF-alpha Neutralizing Monoclonal Antibodies; Clinical Nutrition, GB, Churchill, Livingston, London; 1997	
	-	CHO, et al; Identification of Novel Susceptibility Loci for Inflammatory Bowel disease on Chromosomes 1p, 3q, and 4q: Evidence for Epistasis Between 1p and IBD1; Proceedings of the National Academy of Sciences of the United States; vol 95, no. 13; June 23, 1998; pages 7502-7507	
	-	KOMATA, et al; Association of Tumor Necrosis Factor Receptor 2 (TNFR2) Polymorphism with Susceptibility to systemic Lupus Erythematosus; Tissue Antigens, Vol 53, No. 6; June 1999; pages 527-533	
	-	PANTELIDIS, et al.; Polymorphic Analysis of the High-Affinity Tumor Necrosis Factor Receptor 2; Tissue Antigens, Vol 54, Dec. 1999; pages 585-591	
	-	AL-ANSARI, et al.; Tumor Necrosis Factor Receptor II (TNFR2) Exon 6 Polymorphism in systemic Lupus Erythematosus; Tissue Antigens, Vol 55, No. 1; January 2000, pages 97-99	
LS	-	LOUIS, et al.; Tumour Necrosis Factor (TNF) Gene Polymorphism in Crohn's Disease (CD): Influence on Disease Behaviour?; Clinical and Experimental Immunology, Vol 119, No. 1, January 2000; pages 64-68	

Examiner Signature		Date Considered	10/16/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/902,176
		Filing Date	July 10, 2001
		First Named Inventor	Stefan Schreiber
		Art Unit	1634
		Examiner Name	Sally A. Sakelarlis
Sheet 1 of 1	Attorney Docket Number	25481-P001US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
46		ELLIOT, et al; Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994. <i>IN IDS on 12/14/04 DUPLICATE</i>	
		FABRIS, et al.; Tumor Necrosis Factor-alpha Receptor II Polymorphism in Patients from Southern Europe with Mild-Moderate and Severe Rheumatoid Arthritis; <a href="http://www.jrheum.com/subscribers/02/09/1847.html">http://www.jrheum.com/subscribers/02/09/1847.html</a> ; December 14, 2004 "DUPLICATE"	
		OGILVIE, et al.; Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate; British Journal of Dermatology 2001; 144: 587-589; UK "DUPLICATE"	
		YEE, et al.; Treatment of Complicated Sarcoidosis with Infliximab Anti-tumor Necrosis Factor-Alpha Therapy; Annals of Internal Medicine; <a href="http://www.annals.org/cgi8/content/full/135/1/27">http://www.annals.org/cgi8/content/full/135/1/27</a> ; December 14, 2004 "DUPLICATE"	
		ARINGER, et al.; Safety and Efficacy of Tumor Necrosis Factor Alpha Blockade in Systemic Lupus Erythematosus; Arthritis & Rheumatism; American College of Rheumatology; Vol. 50, No. 10, October 2004; pp 3161-3169; US "DUPLICATE"	
46		RUTGEERTS, et al.; Treatment of active Crohn's diseases with oncept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study; Ailimentary Pharmacology & Therapeutics; Volume 17, Issue 2, Page 185, January 2003; <a href="http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-2036.2003.01414.x/full/">http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-2036.2003.01414.x/full/</a> "DUPLICATE"	

Examiner Signature		Date Considered	6/16/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.